TEL AVIV, Israel, July 26, 2018 /PRNewswire/ -- Galmed
Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a
clinical-stage biopharmaceutical company focused on the development
of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral
therapy for the treatment of nonalcoholic steatohepatitis, or NASH,
announced today that it will host a conference call and webcast on
Thursday, August 2, 2018, to provide
an update on current developments with respect to its clinical
programs for Aramchol™ and to discuss financial results for the
three and six months ended June 30,
2018.
Conference Call & Webcast:
Thursday, August 2
@8:30am Eastern Time
Within the US: 888-394-8218
Outside the US: 323-701-0225
From Israel: 1809-212-883
Conference ID: 5856233
Webcast: http://public.viavid.com/index.php?id=130659
Replays, Available through August
16:
Domestic: 844-512-2921
International: 412-317-6671
Replay PIN: 5856233
About Aramchol™ and Non-alcoholic Steatohepatitis
(NASH)
Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid
bile acid conjugate, inducing beneficial modulation of
intra-hepatic lipid metabolism. Aramchol™'s ability to modulate
hepatic lipid metabolism was discovered and validated in animal
models, demonstrating down regulation of the three key pathologies
of NASH; steatosis, inflammation and fibrosis. The effect of
AramcholTM on fibrosis is mediated by down regulation of steatosis
and directly on human collagen producing cells. Aramchol™ has been
granted by the FDA Fast Track designation status for the treatment
of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5%
of the U.S. population and an estimated 2% to 4% globally. It is
the fastest growing cause of liver cancer and liver transplant in
the U.S. due to the rise in obesity. NASH is the progressive form
of non-alcoholic fatty liver disease that can lead to
cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on
the development of Aramchol, a first in class, novel, once-daily,
oral therapy for the treatment of NASH for variable populations.
Galmed recently announced top-line results of the ARREST Study, a
multicenter, randomized, double blind, placebo-controlled Phase IIb
clinical study designed to evaluate the efficacy and safety of
Aramchol in subjects with NASH, who are overweight or obese, and
who are pre-diabetic or type-II-diabetic. Galmed is currently
preparing for an end of Phase IIb meeting with the FDA to discuss
the results of the ARREST Study and a Phase III study protocol,
with a view to initiating a Phase III clinical study of Aramchol in
2019.
View original
content:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-second-quarter-2018-financial-results-and-provide-business-update-on-thursday-august-2-300686942.html
SOURCE Galmed Pharmaceuticals Ltd.